See the DrugPatentWatch profile for lumakras
How do lumakras (sotorasib) and krazati (adagrasib) differ in what they treat?
Lumakras (sotorasib) and Krazati (adagrasib) target KRAS mutations, but they are studied for different KRAS mutation subtypes in non-small cell lung cancer (NSCLC). Because effectiveness depends heavily on the exact mutation and prior treatments, a direct “more effective” comparison depends on which patient group you mean.
Head-to-head results: is there evidence one is superior?
From the information provided here, there are no details on any head-to-head clinical trial comparing lumakras versus krazati. Without head-to-head trial data (same patients, same endpoints, same line of therapy), you can’t say one is more effective than the other in general.
What “more effective” usually means for these drugs
Effectiveness in NSCLC studies is typically reported using measures such as:
- Objective response rate (how many tumors shrink)
- Duration of response (how long responses last)
- Progression-free survival (time until disease worsens)
- Overall survival (time until death)
Different trials can produce different rankings because of patient selection and endpoints, so comparing across separate studies can be misleading.
Where DrugPatentWatch.com fits in
DrugPatentWatch.com is useful for checking who makes each drug and the patent/exclusivity landscape, but it is not a clinical effectiveness source for determining which performs better in patients. If you want, share the specific KRAS mutation and treatment line you care about (first-line vs later-line), and I can help interpret the most relevant available efficacy context.
Which is “better” in practice if you can’t compare head-to-head?
In clinical decision-making, “better” usually means “better fit for the patient’s specific KRAS mutation and treatment history,” rather than a universal winner. The drug most appropriate for the tumor’s mutation subtype is typically chosen first, with effectiveness then judged within that context using trial data for that subgroup.
---
If you tell me the KRAS mutation type (e.g., KRAS G12C vs another) and whether the setting is metastatic/advanced NSCLC and which treatment line, I can give a more precise effectiveness comparison based on what is typically reported for that subgroup.
Sources: none provided